RAMM Pharma Corp.
RAMM
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 436.50K | 642.90K | 606.20K | 710.80K | 748.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 436.50K | 642.90K | 606.20K | 710.80K | 748.00K |
| Cost of Revenue | 95.60K | 642.50K | 499.20K | 553.90K | 366.10K |
| Gross Profit | 340.90K | 300.00 | 107.00K | 156.90K | 381.90K |
| SG&A Expenses | 1.39M | 687.40K | 695.40K | 1.01M | 3.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 45.90K | 3.30K | 5.20K | 3.70K | 71.50K |
| Total Operating Expenses | 1.53M | 1.33M | 1.20M | 1.57M | 3.61M |
| Operating Income | -1.09M | -690.40K | -593.60K | -859.30K | -2.86M |
| Income Before Tax | -5.15M | -380.70K | -79.90K | -782.30K | -8.40M |
| Income Tax Expenses | 7.70K | -- | 66.00K | -62.80K | 5.90K |
| Earnings from Continuing Operations | -5.16M | -380.70K | -145.90K | -719.50K | -8.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.16M | -380.70K | -145.90K | -719.50K | -8.41M |
| EBIT | -1.09M | -690.40K | -593.60K | -859.30K | -2.86M |
| EBITDA | -1.02M | -592.30K | -467.90K | -728.10K | -2.83M |
| EPS Basic | -0.04 | 0.00 | 0.00 | -0.01 | -0.07 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.02 |
| EPS Diluted | -0.04 | 0.00 | 0.00 | -0.01 | -0.07 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.02 |
| Average Basic Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.39M | 119.39M |
| Average Diluted Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.39M | 119.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |